Recurrent Adult Acute Myeloid Leukemia Clinical Trials

186 clinical trials for Recurrent Adult Acute Myeloid Leukemia across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Personalized NK Cell Therapy in CBT — RECRUITING · PHASE2
• A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma — RECRUITING · PHASE1
• CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML — RECRUITING · NA
• Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission — COMPLETED · PHASE3
• Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML — ACTIVE_NOT_RECRUITING · PHASE2
• Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent — TERMINATED · PHASE2
• Biomarkers in Predicting Treatment Response to Sirolimus and Chemotherapy in Patients With High-Risk Acute Myeloid Leukemia — COMPLETED · PHASE2
• A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies — COMPLETED · PHASE2
• A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia — COMPLETED · PHASE1
• Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant — SUSPENDED · PHASE1
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia — TERMINATED · PHASE1
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant — ACTIVE_NOT_RECRUITING
• Sirolimus and Azacitidine in Treating Patients With High Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia That is Recurrent or Not Eligible for Intensive Chemotherapy — COMPLETED · PHASE2
• Veliparib and Temozolomide in Treating Patients With Acute Leukemia — COMPLETED · PHASE1
• Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies — COMPLETED · PHASE2
• Nintedanib and Azacitidine in Treating Participants With HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm — ACTIVE_NOT_RECRUITING · PHASE1
• Total Marrow and Lymphoid Irradiation and Chemotherapy Before Donor Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Leukemia — COMPLETED · PHASE1
• Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant — TERMINATED · PHASE1
• Veliparib and Topotecan With or Without Carboplatin in Treating Patients With Relapsed or Refractory Acute Leukemia, High-Risk Myelodysplasia, or Aggressive Myeloproliferative Disorders — COMPLETED · PHASE1
• CPI-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma — COMPLETED · PHASE1
• Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia — TERMINATED · PHASE1
• Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant — COMPLETED · PHASE1
• Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts in Preventing GVHD in Children — COMPLETED · PHASE2
• Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer — TERMINATED · PHASE1
• Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies — COMPLETED · PHASE1
• Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies — COMPLETED · PHASE1
• Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer — TERMINATED · PHASE2
• Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia — COMPLETED · PHASE1
• Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome — TERMINATED · PHASE2
• Metabolic Changes in Blood Samples From Patients With Acute Myeloid Leukemia — COMPLETED
• Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia — COMPLETED · PHASE1
• Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia — COMPLETED · PHASE2
• Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia — TERMINATED · PHASE1
• Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant — TERMINATED · PHASE1
• Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia — TERMINATED · PHASE1
• PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell Transplant — COMPLETED · PHASE2
• EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia — TERMINATED · PHASE1
• Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia — COMPLETED · PHASE2
• AML Therapy With Irradiated Allogeneic Cells — TERMINATED · NA
• Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia — COMPLETED · PHASE2
• Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia — COMPLETED · PHASE1
• High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors — COMPLETED · NA
• Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia — COMPLETED · PHASE3
• Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer — COMPLETED · PHASE2
• Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia — COMPLETED · PHASE1
• Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy — COMPLETED · PHASE2

Refine this search